Donald L. Hagan, LLC Gilead Sciences, Inc. Transaction History

Donald L. Hagan, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Jan 17, 2023	SELL	$62.32 - $89.47 $16,577 - $23,799	-266 Reduced 1.35%	19,504 $0
Q3 2022 Oct 12, 2022	BUY	$59.54 - $68.01 $1,250 - $1,428	21 Added 0.11%	19,770 $1.22 Million
Q2 2022 Jul 20, 2022	BUY	$57.72 - $65.01 $71,976 - $81,067	1,247 Added 6.74%	19,749 $1.22 Million
Q1 2022 Apr 18, 2022	BUY	$57.92 - $72.58 $59,599 - $74,684	1,029 Added 5.89%	18,502 $1.1 Million
Q4 2021 Jan 20, 2022	BUY	$64.88 - $73.64 $50,606 - $57,439	780 Added 4.67%	17,473 $1.27 Million
Q3 2021 Oct 20, 2021	BUY	$67.69 - $73.03 $11,507 - $12,415	170 Added 1.03%	16,693 $1.17 Million
Q2 2021 Jul 19, 2021	BUY	$63.47 - $69.35 $500,207 - $546,547	7,881 Added 91.19%	16,523 $1.14 Million
Q1 2021 Apr 27, 2021	BUY	$60.0 - $68.46 $518,520 - $591,631	8,642 New	8,642 $559,000

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Donald L. Hagan, LLC, based on Form 13F filings with the SEC.

Stay updated on Donald L. Hagan, LLC with notifications on news.